HomeCompareIPNAF vs MRK

IPNAF vs MRK: Dividend Comparison 2026

IPNAF yields 2.14% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $3.2K in total portfolio value
10 years
IPNAF
IPNAF
● Live price
2.14%
Share price
$5.75
Annual div
$0.12
5Y div CAGR
37.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.5K
Annual income
$11,456.64
Full IPNAF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — IPNAF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPNAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPNAF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPNAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPNAF
Annual income on $10K today (after 15% tax)
$181.55/yr
After 10yr DRIP, annual income (after tax)
$9,738.14/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, IPNAF beats the other by $1,141.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPNAF + MRK for your $10,000?

IPNAF: 50%MRK: 50%
100% MRK50/50100% IPNAF
Portfolio after 10yr
$56.1K
Annual income
$10,785.21/yr
Blended yield
19.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IPNAF
No analyst data
Altman Z
10.8
Piotroski
3/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPNAF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPNAFMRK
Forward yield2.14%2.81%
Annual dividend / share$0.12$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37.7%32.7%
Portfolio after 10y$54.5K$57.7K
Annual income after 10y$11,456.64$10,113.78
Total dividends collected$30.7K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IPNAF vs MRK ($10,000, DRIP)

YearIPNAF PortfolioIPNAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,994$294.10$11,213$373.04$219.00MRK
2$12,180$416.11$12,667$512.06$487.00MRK
3$13,626$593.25$14,439$708.14$813.00MRK
4$15,434$854.10$16,640$988.16$1.2KMRK
5$17,759$1,244.99$19,432$1,394.07$1.7KMRK
6$20,846$1,843.60$23,057$1,992.90$2.2KMRK
7$25,090$2,784.93$27,889$2,894.79$2.8KMRK
8$31,160$4,313.67$34,518$4,286.29$3.4KMRK
9$40,235$6,894.36$43,912$6,494.35$3.7KMRK
10$54,508$11,456.64$57,714$10,113.78$3.2KMRK

IPNAF vs MRK: Complete Analysis 2026

IPNAFStock

Information Planning CO., LTD. provides system consulting services primarily for financial institutions. It offers credit risk management related products, including comprehensive financial statement registration solution, collateral/real estate management, self-assessment/delinquency management, and risk measurement solutions. The company also provides loan related products, such as loan approval support, contract create support, benchmark aggregation, business feasibility evaluation support, and public relations support map systems; general affairs/accounting related products comprising fixed asset management, settlement business support, anti-social forces information check, investment management, expense payment office work support, and securities management systems; and tax/accounting related products, such as real-time connection and fixed asset management systems. In addition, it engages in the real estate leasing and management activities; and provision of development, planning, and system data input agency services. Information Planning CO., LTD. was incorporated in 1986 and is headquartered in Osaka, Japan.

Full IPNAF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this IPNAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPNAF vs SCHDIPNAF vs JEPIIPNAF vs OIPNAF vs KOIPNAF vs MAINIPNAF vs JNJIPNAF vs ABBVIPNAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.